Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.

ASX Announcements (7d)

-

Twitter Mentions (7d)

0+

AFR Articles (7d)

-

News Articles (7d)

1+
Subject
TLX Article: Telix boss says Australia ‘horrible’ at getting drugs to patients

TLX Article: Telix upsizes convertibles deal to $650m; delta block clears at $18.70

TLX Article: Telix shares hit new high on upgraded revenue forecast

TLX Article: Why $3b Aussie darling Telix needs to grow wings

TLX Article: ASX posts worst start to year since 2007 as December rally cools

TLX Article: ASX edges higher; Core Lithium sinks on mine halt; BlueBet jumps 25pc

TLX Article: ASX edges higher; Core Lithium sinks on mine halt; BlueBet jumps 25pc

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Proposed issue of securities - TLX

TLX Ann: Lightpoint Acquisition to Expand Telix Urologic Pipeline

TLX Ann: Telix Urology Innovation Showcase

TLX Ann: Phase II study for indication expansion of TLX250-CDx doses

TLX Article: Why this CEO thinks 454pc growth in his company is just the beginning

TLX Ann: Appendix 3Y Change in Director Interests - C Behrenbruch

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Securities Dealing Policy - updated

TLX Ann: Results of Annual General Meeting

TLX Ann: Annual General Meeting - Presentation

TLX Ann: Annual General Meeting - Chairman and CEO Addresses

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses

TLX Ann: Proposed issue of securities - TLX

TLX Ann: Presentation to Accompany AI Development Program Update

TLX Ann: Telix Accelerates AI Development with Dedicaid Acquisition

TLX Ann: AGM Notice of Meeting, Proxy Form and Online Guide

TLX Ann: Q1 2023 Business update to accompany quarterly results

TLX Ann: Appendix 4C and Activities Report - March 2023 Quarter

TLX Ann: Telix-Grand Pharma Investor Webcast Notification

TLX Ann: Telix Preclinical Development of Radiolabelled Olaratumab

TLX Ann: Notification of upcoming quarterly results and investor call

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Illuccix European Marketing Authorisation Application Update

TLX Ann: Non-Executive Director Leave of Absence

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: App 3Y Change in Director Interests - T Olson

TLX Ann: FDA approval of expanded indication of Illuccix in the US

TLX Ann: Date of 2022 AGM

TLX Ann: Corporate governance statement - Appendix 4G

TLX Ann: 2022 Full Year Results Presentation

TLX Ann: 2022 Full Year Results Release

Register to track TLX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC